Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Ruberg

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Statistics in Medicine|July 21, 2016
Estimands in clinical trials - broadening the perspectiveMouna Akacha, Frank Bretz, Stephen Ruberg
Pharmaceutical Statistics|July 27, 2007
Partition testing in dose-response studies with multiple endpointsYi Liu, Jason Hsu, Stephen Ruberg
Biometrical Journal. Biometrische Zeitschrift|May 6, 2023
A platform for comparing subgroup identification methodologiesStephen Ruberg, Ying Zhang, Hollins Showalter, et al.
Journal of Biopharmaceutical Statistics|March 16, 2012
A portfolio-based approach to optimize proof-of-concept clinical trialsCraig Mallinckrodt, Geert Molenberghs, Charles Persinger, et al.
Pharmaceutical Statistics|October 29, 2020
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysisMark Rothmann, William Crown, Thomas A Louis, et al.
Schizophrenia Research|July 1, 2009
Optimal thresholds of early response to atypical antipsychotics: application of signal detection methodsLei Chen, Haya Ascher-Svanum, Virginia Stauffer, et al.
Pharmaceutical Statistics|January 11, 2020
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPDOliver N Keene, Stephen Ruberg, Alexander Schacht, et al.
Pharmaceutical Statistics|December 27, 2024
WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial SponsorsKonstantinos Sechidis, Sophie Sun, Yao Chen, et al.
Biometrical Journal. Biometrische Zeitschrift|September 22, 2023
CITIES: Clinical trials with intercurrent events simulatorAhmad Hakeem Abdul Wahab, Yongming Qu, Hege Michiels, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Statistics in Medicine|July 21, 2016
Estimands in clinical trials - broadening the perspectiveMouna Akacha, Frank Bretz, Stephen Ruberg
Pharmaceutical Statistics|July 27, 2007
Partition testing in dose-response studies with multiple endpointsYi Liu, Jason Hsu, Stephen Ruberg
Biometrical Journal. Biometrische Zeitschrift|May 6, 2023
A platform for comparing subgroup identification methodologiesStephen Ruberg, Ying Zhang, Hollins Showalter, et al.
Journal of Biopharmaceutical Statistics|March 16, 2012
A portfolio-based approach to optimize proof-of-concept clinical trialsCraig Mallinckrodt, Geert Molenberghs, Charles Persinger, et al.
Pharmaceutical Statistics|October 29, 2020
Assessing and communicating heterogeneity of treatment effects for patient subpopulations: Panel discussion on considerations in design and analysisMark Rothmann, William Crown, Thomas A Louis, et al.
Schizophrenia Research|July 1, 2009
Optimal thresholds of early response to atypical antipsychotics: application of signal detection methodsLei Chen, Haya Ascher-Svanum, Virginia Stauffer, et al.
Pharmaceutical Statistics|January 11, 2020
What matters most? Different stakeholder perspectives on estimands for an invented case study in COPDOliver N Keene, Stephen Ruberg, Alexander Schacht, et al.
Pharmaceutical Statistics|December 27, 2024
WATCH: A Workflow to Assess Treatment Effect Heterogeneity in Drug Development for Clinical Trial SponsorsKonstantinos Sechidis, Sophie Sun, Yao Chen, et al.
Biometrical Journal. Biometrische Zeitschrift|September 22, 2023
CITIES: Clinical trials with intercurrent events simulatorAhmad Hakeem Abdul Wahab, Yongming Qu, Hege Michiels, et al.
Pageof 1